Avidity Biosciences Inc Ordinary Shares RNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNA is a good fit for your portfolio.
News
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
-
Avidity Biosciences Honors Rare Disease Day®
-
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $24.34
- Day Range
- $24.52–25.50
- 52-Week Range
- $4.84–27.65
- Bid/Ask
- $22.57 / $26.95
- Market Cap
- $1.97 Bil
- Volume/Avg
- 437,149 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 186.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 253
Comparables
Valuation
|
Metric
|
RNA
|
DYN
|
TRDA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 109.80 |
Price/Book Value | 3.86 | 16.65 | 1.72 |
Price/Sales | 186.04 | — | 3.19 |
Price/Cash Flow | — | — | 117.97 |
Price/Earnings
RNA
DYN
TRDA
Financial Strength
|
Metric
|
RNA
|
DYN
|
TRDA
|
|---|---|---|---|
Quick Ratio | 7.49 | 2.41 | 2.25 |
Current Ratio | 7.58 | 2.53 | 2.33 |
Interest Coverage | — | — | — |
Quick Ratio
RNA
DYN
TRDA
Profitability
|
Metric
|
RNA
|
DYN
|
TRDA
|
|---|---|---|---|
Return on Assets (Normalized) | −28.38% | −88.69% | 0.84% |
Return on Equity (Normalized) | −32.05% | −114.25% | 1.61% |
Return on Invested Capital (Normalized) | −35.80% | −102.56% | −3.00% |
Return on Assets
RNA
DYN
TRDA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Klkpcttf | Vqfg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fymcxkkdv | Hnqrhfm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wpqtsjzr | Qzsqz | $97.8 Bil | |
MRNA
| Moderna Inc | Jjrjlbsy | Thgt | $41.3 Bil | |
ARGX
| argenx SE ADR | Wdxcxdd | Gjb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fdmtchh | Vpvkh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lyzdtkvl | Kbstwm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qqppltmm | Lgzkvhc | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Czcxnrdsfz | Ztfwnj | $12.5 Bil | |
INCY
| Incyte Corp | Hsjrdwgh | Grxqfs | $11.6 Bil |